Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer: Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). The recommended first-line therapy for HER2-positive metastatic breast cancer consists of the anti-HER2 monoclonal antibodies trastuzumab and…